The SCRIPPS DES REAL WORLD Registry

Coronary Artery Disease Clinical Trial

Official title:

A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00714623
• Other study ID #: 04-048
• Status: Completed
• Phase: N/A
• First received: July 9, 2008
• Last updated: December 20, 2012
• Start date: March 2005
• Est. completion date: April 2012

Study information

• Verified date: December 2012
• Source: Scripps Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

This study is a prospective, non-randomized, open-label registry of consecutive patients with CAD treated by stent-assisted PCI using at least one CypherTM stent. Up to 1000 pts will be included in the registry. The registry is conducted for the evaluation of the impact of CypherTM Sirolimus-eluting stent implantation in the "real world" of interventional cardiology. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study specific procedures. Consecutive patients treated with the use of the CypherTM stent will be included in the registry. Baseline and post-procedure blood samples will be used to perform platelet function analysis using the Accumetrics Ultegra RPFA (Rapid Platelet Function Assay).

All patients will be followed from enrollment through the hospital discharge for any clinically significant event (death, myocardial infarction, TLR, TVR, major or minor bleeding). A follow-up telephone assessment of death, myocardial infarction, revascularization, and medical treatment will be conducted by experienced research personnel at 30 days, 6 months, 1 year and at least 2 years. All site reported deaths, myocardial infarctions and revascularizations will be adjudicated by an independent Clinical Events Committee for all 1000 patients enrolled in the trial. An interim analysis of the first 750 patients will be conducted and data forwarded to FDA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 859
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or older

2. Eligible for percutaneous coronary intervention

3. Patient has at least one lesion =50% diameter stenosis requiring PCI with stenting

4. Reference vessel diameter 2.25-4.0 mm

5. Percutaneous intervention with use of one or more of the FDA approved CypherTM stents, planned not to exceed 108 mm of stent length.

6. Target lesion is located within a native coronary artery or bypass graft

7. De novo and restenotic lesions, including ISR, radiation failure

8. Be reliable, cooperative and willing to comply with all protocol-specified procedures and follow-up

9. Able to understand and grant informed consent

Exclusion Criteria:

1. Confirmed pregnancy at the time of index PCI

2. Has known allergies to aspirin, and to both clopidogrel (PlavixTM) and ticlopidine (TiclidTM)

3. Has known allergies or contraindication to heparin and Bivalirudin (AngiomaxTM)

4. Known allergy or sensitivity to any component of a Sirolimus-eluting stent

5. Has a significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;

6. Any serious disease condition with life expectancy of less than 1 year.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Coronary Restenosis
• Coronary Thrombosis
• Myocardial Ischemia
• Thrombosis

Intervention

Device:
• Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.

Locations

Country	Name	City	State
United States	Scripps Green Hospital/Scripps Clinic Torrey Pines	La Jolla	California

Sponsors (2)

Lead Sponsor	Collaborator
Paul S Teirstein, MD	Cordis Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1 yr target vessel failure (TVF), defined as the occurrence of any of the following within 1-year after the index procedure: death from cardiac causes, Q-wave or non-Q wave MI attributable to the target vessel (TV), or revascularization of the TV.		1 year	Yes